000132840 001__ 132840
000132840 005__ 20241125101152.0
000132840 0247_ $$2doi$$a10.1038/s41433-023-02795-3
000132840 0248_ $$2sideral$$a137768
000132840 037__ $$aART-2023-137768
000132840 041__ $$aeng
000132840 100__ $$aKreps, E.O.
000132840 245__ $$aInfliximab in chronic non-infectious paediatric uveitis refractory to previous biologic therapy
000132840 260__ $$c2023
000132840 5060_ $$aAccess copy available to the general public$$fUnrestricted
000132840 5203_ $$aObjectives
To examine the outcome of infliximab treatment in patients with non-infectious paediatric uveitis who have previously failed biologic treatment.
Methods
A retrospective cohort study was performed at Bristol Eye Hospital, UK. Paediatric patients with chronic non-infectious uveitis who had been switched to infliximab due to inadequate uveitis control were identified. Two separate groups were evaluated: group 1 consisted of 20 children (36 eyes) who had been switched to infliximab following treatment failure with adalimumab (=in-class switching), while group 2 (5 patients; 9 eyes) included those who had been switched to infliximab from a non-TNF antagonist after failing several biologics (=across-class switching). The change in anterior chamber (AC) activity between baseline and 6- and 24-months follow-up was the primary outcome measure.
Results
A statistically significant reduction in AC activity was found between baseline and 6-months follow-up (RE: p = 0.002; LE: p < 0.001) and between baseline and 24-months follow-up (RE: p = 0.016; LE: p = 0.011) in group 1. No statistically significant difference was found for either eye in the number of steroid eye drops needed between time points or the difference in visual acuity in time. In group 2, analysis of change of AC activity, number of steroid eye drops and visual acuity failed to reach statistical significance. Treatment failure occurred in four patients (20% of group 1) and adverse events developed in six patients including three patients with acute infusion reactions.
Conclusions
This study supports the efficacy and safety of infliximab in adalimumab-refractory patients with paediatric non-infectious uveitis.
000132840 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000132840 590__ $$a2.8$$b2023
000132840 592__ $$a1.373$$b2023
000132840 591__ $$aOPHTHALMOLOGY$$b24 / 95 = 0.253$$c2023$$dQ2$$eT1
000132840 593__ $$aArts and Humanities (miscellaneous)$$c2023$$dQ1
000132840 593__ $$aSensory Systems$$c2023$$dQ1
000132840 593__ $$aOphthalmology$$c2023$$dQ1
000132840 593__ $$aMedicine (miscellaneous)$$c2023$$dQ1
000132840 594__ $$a6.4$$b2023
000132840 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000132840 700__ $$aEpps, S.J.
000132840 700__ $$0(orcid)0000-0001-5186-1837$$aConsejo, A.$$uUniversidad de Zaragoza
000132840 700__ $$aDick, A.D.
000132840 700__ $$aGuly, C. M.
000132840 700__ $$aRamanan, A.V.
000132840 7102_ $$12002$$2385$$aUniversidad de Zaragoza$$bDpto. Física Aplicada$$cÁrea Física Aplicada
000132840 773__ $$g38 (2023), 871–876$$pEye$$tEye (Basingstoke)$$x0950-222X
000132840 8564_ $$s500063$$uhttps://zaguan.unizar.es/record/132840/files/texto_completo.pdf$$yVersión publicada
000132840 8564_ $$s2709565$$uhttps://zaguan.unizar.es/record/132840/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000132840 909CO $$ooai:zaguan.unizar.es:132840$$particulos$$pdriver
000132840 951__ $$a2024-11-22-12:07:16
000132840 980__ $$aARTICLE